In a xenograft model of TNBC, RGD peptide-directed siRNA-loaded nanoparticles targeting ITGB3 have significant therapeutic benefits, and lipid nanoparticles with ITGAV and ITGB1-targeted siRNA suppress hepatocellular cancer in vivo. This evidence concerns the gene ITGB1 and hepatocellular carcinoma.